Patient Information
This clinical report evaluates a cohort of 1,351 women at high risk for ovarian cancer, predominantly due to inherited susceptibility or a strong family history. Among this group, 984 individuals were confirmed carriers of pathogenic variants in the BRCA1 or BRCA2 genes. The patients underwent risk-reducing salpingo-oophorectomy (RRSO) as a prophylactic measure according to clinical guidelines, which typically recommend the procedure between ages 35 and 40 for BRCA1 carriers and between 40 and 45 for BRCA2 carriers. The total follow-up duration for this cohort was 7,433.3 woman-years.
Diagnosis
The diagnosis was centered on the histopathological evaluation of surgical specimens obtained during RRSO. A specialized review of the fallopian tubes was conducted to identify Serous Tubal Intraepithelial Carcinoma (STIC), which is considered a precursor lesion to high-grade serous carcinoma.
Out of the cohort, 14 patients were diagnosed with STIC at the time of their RRSO (10 were BRCA1 carriers; 2 were BRCA2 carriers). Additionally, some patients were found to have occult invasive carcinoma. The diagnosis of Peritoneal Carcinoma (PC) was made post-operatively during the follow-up period in 4 specific cases within the cohort.
Differential Diagnosis
In the context of high-risk prophylactic surgery, the differential diagnosis focuses on distinguishing between:
1. **Benign Findings:** Normal age-related changes or non-malignant pathology (median age of 51 in this study).
2. **Serous Tubal Intraepithelial Carcinoma (STIC):** Non-invasive malignant cells confined to the tubal epithelium (median age of 54 in this study).
3. **Occult Invasive Carcinoma:** Small, previously undetected invasive cancer already present at the time of RRSO (median age of 55 in this study).
4. **Primary Peritoneal Carcinoma (PPC):** Malignancy arising from the peritoneal lining rather than the ovaries or tubes, often occurring after RRSO.
Treatment and Management
The primary intervention was Risk-Reducing Salpingo-Oophorectomy (RRSO), involving the complete removal of both ovaries and fallopian tubes. For patients where STIC was detected, management shifted from standard prophylaxis to intensive surveillance.
The study emphasizes the necessity of a meticulous surgical and pathological protocol, often referred to as the SEE-FIM (Sectioning and Extensively Examining the FIMbrial end) protocol, to ensure no micro-lesions are missed. Current management strategies for those with STIC include discussing the potential for staging surgery or implementing rigorous monitoring through CA125 serum markers and imaging, though the efficacy of these secondary measures remains a subject of ongoing research.
Outcome and Prognosis
The overall 5-year cumulative incidence of peritoneal carcinoma after RRSO was low at 0.4% for the general high-risk cohort and 0.5% specifically for BRCA1/2 carriers. However, the prognosis changed dramatically for women with STIC detected at the time of surgery; these patients faced a 11.1% 5-year risk of developing peritoneal carcinoma.
The study also noted a correlation between age and pathological findings. The median age for those with benign findings was 51, compared to 54 for STIC and 55 for invasive carcinoma, reinforcing that delayed surgery increases the likelihood of finding advanced lesions.
Discussion
This large-scale multicenter study confirms that RRSO significantly reduces but does not entirely eliminate the risk of peritoneal malignancy. The discovery of STIC is a critical prognostic factor, identifying a subgroup of women at a substantially higher risk (over 10%) of developing peritoneal cancer within five years of their prophylactic surgery.
The data supports the “tubal origin” theory of high-grade serous ovarian cancer, where many peritoneal and ovarian cancers actually begin in the fimbriated end of the fallopian tube. The findings highlight three major clinical takeaways:
1. **Timing of Surgery:** Adherence to recommended age windows (35-45 depending on mutation) is vital, as the risk of finding STIC or invasive cancer increases with age.
2. **Pathological Rigor:** Pathologists must use exhaustive sectioning techniques on fallopian tubes to detect STIC.
3. **Post-Surgical Monitoring:** Women found to have STIC require a tailored, intensive follow-up protocol. Future directions may include the use of innovative markers such as circulating tumor DNA (ctDNA) to detect early recurrence or progression in these high-risk individuals.
References
1. Saule C, Laas E, Weber N, et al. Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions. Gynecologic oncology. 2026;208:1-7. PMID: 41818853.
2. Rebbeck TR, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015.
3. National Comprehensive Cancer Network (NCCN) Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic.
